Bright Green Announces CEO Transition

Ed Robinson to resign; Terry Rafih, Chairman of Bright Green’s Board of Directors, to Take Over as Interim CEO

The Board of Directors launches a thorough search for a permanent successor

GRANTS, New Mexico, July 01. 12, 2022 (GLOBE NEWSWIRE) — Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or “the Company”), one of the very few companies selected by the U.S. government to develop, manufacture, and sell, legally in under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today announced that Ed Robinson is stepping down as CEO and member of the board of directors (board of directors), to pursue other opportunities. Mr. Robinson will remain with the company as a financial markets advisor until 2023.

The board has launched an extensive search to identify a permanent CEO. Until a successor is named, the board has named board chairman Terry Rafih as interim CEO.

“We thank Ed for his dedication and hard work in guiding Bright Green through an important period of growth. Under his leadership, the company completed a direct listing on the Nasdaq in May 2022, has made notable progress as it prepares to cultivate, manufacture and market federally compliant cannabis, and is positioned to advance its development of ‘innovative and advanced agricultural ecosystems for medicinal plants,’” said Chairman of the Board and Interim CEO, Terry Rafih. “The Board of Directors is pleased to select a successor to oversee the company’s next phase of growth.

Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date first issued and are based on expectations, estimates, forecasts and projections as well as management’s beliefs and assumptions. Words such as “expect”, “anticipate”, “should”, “believe”, “hope”, “target”, “project”, “goals”, “estimate”, “potential”, “predict” , “may,” “will,” “could,” “could,” “intend,” “shall” and variations of these terms or the negative form of these terms and similar expressions are intended to identify these statements forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances beyond the company’s control. The company’s actual results could differ materially from those indicated or implied. in forward-looking statements due to a number of factors, including, but not limited to, the risks detailed in the company’s registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on May 11, 2022 and in the quarterly report of the Company on Form 10-Q filed with the SEC on June 7, 2022, and such other documents as may be filed by the Company from time to time with the SEC. The forward-looking statements included in this press release represent the views of the company as of the date of this press release. The company anticipates that subsequent events and developments will cause a change of opinion. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be taken to represent the views of the company as of any date subsequent to the date of this press release. Additional information regarding these and other factors that could affect the Company’s results is included in the Company’s filings with the SEC, which may be obtained by visiting the SEC’s website at www.

About Bright Green
Bright Green is one of the few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications, and affiliated export. . Our conditional approval based on previously agreed upon conditions from the United States Drug Enforcement Administration gives us the opportunity to advance our vision of improving quality of life through the opportunities afforded by cannabis-derived therapies. To learn more, visit

Media Contact
[email protected]

Investor Relations
[email protected]

More Stories
What channel is the Kentucky Derby airing on? TV coverage, live stream and more to watch the 2022 race